Why These 15 Stocks Are Skyrocketing in 2025

4. Vir Biotechnology (NASDAQ:VIR)

Number of Hedge Fund Holders In Q3 2024: 22

Vir Biotechnology (NASDAQ:VIR) is an immunology company that makes antibody platforms and T-cell engagers. The company focuses on chronic hepatitis delta, chronic hepatitis B, and HIV. It also has “masked” T-cell engagers in clinical trials for some solid tumors.

The recent rise was triggered by its positive early-stage clinical results in oncology. Vir Biotechnology announced in early January that it had encouraging outcomes from its dual-masked T-cell engagers in solid tumors and advanced prostate cancer. Analysts noted that Vir is now aiming to launch a Phase 3 program for its hepatitis delta treatment in the first half of this year and reported over $1.19 billion in cash.

Regardless, like most biotech startups, Vir Biotechnology recorded a net loss in Q3 2024, but the huge cash pile can fund development into mid-2027 despite the losses. Its 2025 consensus revenue estimate is at $33 million, and projected EPS is around -$2.8 for 2025.

The consensus analyst price target is $31.38, which implies 198% upside. However, you should keep in mind that this is biotech and over-the-top price targets are common here.

The stock is up 44.8% year-to-date.